TRAVERE THERAPEUTICSCS INC
Action · US89422G1076 · TVTX · A2QHYP (XNAS)
15,32 USD
06.06.2025 20:00
Cours actuels de TRAVERE THERAPEUTICSCS INC
Bourse | Ticker | Devise | Dernier échange | Cours | Variation journalière |
---|---|---|---|---|---|
![]() NASDAQ |
TVTX
|
USD
|
06.06.2025 20:00
|
15,32 USD
| 14,72 USD
+4,08 %
|
Performance
Jour | Semaine | Mois | 3 mois | 6 mois | 1 an | 5 ans |
---|---|---|---|---|---|---|
0,00 % | 2,00 % | -23,21 % | -19,11 % | -20,29 % | 111,89 % | -5,84 % |
Profil de l'entreprise pour TRAVERE THERAPEUTICSCS INC Action
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Fonds investis
Les fonds suivants ont investi dans : TRAVERE THERAPEUTICSCS INC investi :
Fonds | Vol. en millions 43,83 | Part (%) 0,10 % |
Données de l'entreprise
Nom TRAVERE THERAPEUTICSCS INC
Société Travere Therapeutics, Inc.
Symbole TVTX
Site web
https://www.travere.com
Marché d'origine
NASDAQ

WKN A2QHYP
ISIN US89422G1076
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Dr. Eric M. Dube Ph.D.
Capitalisation boursière 1 Mrd.
Pays États-Unis d'Amérique
Devise USD
Employés 0,4 T
Adresse 3611 Valley Centre Drive, 92130 San Diego
Date d'introduction en bourse 2012-11-08
Changements d'identifiant
Date | De | À |
---|---|---|
19.11.2020 | RTRX | TVTX |
Symboles boursiers
Nom | Symbole |
---|---|
NASDAQ | TVTX |
Autres actions
Les investisseurs qui détiennent TRAVERE THERAPEUTICSCS INC ont également les actions suivantes dans leur portefeuille :
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles.
Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.